161670-39-9

Upstream product

• 6404-29-1 6-(tert-butoxycarbonylamino)hexanoic acid 

Downstream Products

• 1309250-83-6 C₃₃H₆₂N₄O₆ 
• 1309250-96-1 ε-((3S,4S)-4-((3S,4S)-4-((3S,4S)-4-amino-3-hydroxy-6-methylheptanoylamino)-5-cyclohexyl-3-hydroxypentanoylamino)-3-hydroxy-5-phenylpentanoylamino)hexanoic acid N-isoamylamide hydrochloride 
• 1309250-95-0 C₄₃H₈₁N₅O₉ 
• 1309250-91-6 C₂₆H₄₈N₄O₆*ClH 
• 1309250-90-5 C₃₁H₅₆N₄O₈ 
• 1309250-89-2 C₂₈H₅₂N₄O₆*ClH 
• 1309250-88-1 C₃₃H₆₀N₄O₈ 
• 1309250-84-7 C₂₈H₅₄N₄O₄*ClH 
• 161670-37-7 [(S)-1-{[(S)-1-((S)-1-{(S)-1-Hydroxy-2-[5-(3-methyl-butylcarbamoyl)-pentylcarbamoyl]-ethyl}-3-methyl-butylcarbamoyl)-3-methyl-butyl]-methyl-carbamoyl}-2-(4-methoxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 189162-94-5 (3S,4S)-4-((S)-2-{[(S)-2-Amino-3-(4-methoxy-phenyl)-propionyl]-methyl-amino}-4-methyl-pentanoylamino)-3-hydroxy-6-methyl-heptanoic acid [5-(3-methyl-butylcarbamoyl)-pentyl]-amide 

Relevant academic research and scientific papers

New potential renin inhibitors with dipeptide replacements in the molecule

A series of eight non-peptidic potential renin inhibitors have been designed and synthesized. All of them contain dipeptide replacement: (3S,4S)-4-amino-5-cyclohexyl-3-hydroxypentanoic acid (ACHPA) in their molecules. Four among them comprise two additional analogs of dipeptide: (3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid (AHPPA) and (3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid (statine, Sta). All of the synthesized compounds contain also hydrophobic portions to receive a moderate lipophilicity of the molecules. Inhibitory activity of the compounds was measured in vitro by HPLC determination of Leu-Val-Tyr-Ser released from the N-acetyltetradecapeptide substrate by renin in the presence of the inhibitor. Asp-α(OEt)-(S,S)-ACHPA-εAhx-Iaa (23) shows inhibitory activity (7%) at the concentration of 1.0 × 10-2 M. The other synthesized compounds show no inhibitory activity up to this concentration.